Azacitidine Kabi (azacitidine)
- Region
- 🇪🇺 EU
- Active substance
- azacitidine
- Company
- Fresenius Kabi Deutschland GmbH
- Status
- Authorised
- Therapeutic area
- Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
- CHMP opinion
- Fri 10 Nov 2023
- EU approval
- Fri 05 Jan 2024
- Designations
- Generic
- Application
- EMEA/H/C/006154
- ATC
- L01BC07
- Official record
- www.ema.europa.eu
Indication
Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation(HSCT) with: Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the international prognostic scoring system (IPSS), Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder, Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification, AML with > 30% marrow blasts according to the WHO classification.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Onureg Authorised · Bristol-Myers Squibb Pharma EEIG
- 🇪🇺 Azacitidine Adienne Application withdrawn · Adienne S.r.l. S.U.
- 🇪🇺 Azacitidine Mylan Authorised · Mylan Pharmaceuticals Limited
- 🇪🇺 Azacitidine Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Vidaza Authorised · Bristol-Myers Squibb Pharma EEIG
- 🇪🇺 Azacitidine betapharm Authorised · betapharm Arzneimittel GmbH
- 🇪🇺 Azacitidine Celgene Withdrawn · Celgene Europe BV
Follow Azacitidine Kabi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.